Raily Aesthetic Medicine Brings Biomedical Expert Onto Board as INED

An update from Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) is now available.

Raily Aesthetic Medicine International Holdings has appointed biomedical expert Dr. Lin Hai as an independent non-executive director effective March 27, 2026, alongside his roles as chairman of the remuneration committee and member of the audit, nomination and strategic investment committees. His extensive research and product development experience in tissue-inductive biomaterials and medical implants, including collagen and hyaluronic acid, strengthens the company’s governance and technical capabilities.

The company also announced the resignation of independent non-executive director Mr. Cao Dequan, who will cease to hold any position with the firm from the same date. The boardroom reshuffle signals a shift towards deeper scientific and regulatory expertise at the board level, which may support Raily’s innovation pipeline, compliance profile and strategic decision-making in the competitive aesthetic medicine industry.

The most recent analyst rating on (HK:2135) stock is a Hold with a HK$0.15 price target. To see the full list of analyst forecasts on Raily Aesthetic Medicine International Holdings Limited stock, see the HK:2135 Stock Forecast page.

More about Raily Aesthetic Medicine International Holdings Limited

Raily Aesthetic Medicine International Holdings Limited operates in the aesthetic medicine sector, focusing on medical beauty services and related treatments in Greater China. The company positions itself within the fast-growing medical aesthetics market, where technology, clinical expertise, and regulatory compliance are key to differentiation and long-term growth.

Average Trading Volume: 431,953

Technical Sentiment Signal: Hold

Current Market Cap: HK$81.33M

For an in-depth examination of 2135 stock, go to TipRanks’ Overview page.